The largest not-for-profit scientific network of Parkinson centers in North America
Parkinson Study Group has carried out cooperative therapeutic research since 1986, beginning with the NIH-sponsored DATATOP (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism) clinical trial. Since then we have carried out more than 35 multi-center trials examining the symptomatic and neuroprotective effects of experimental interventions in Parkinson disease. The PSG has partnered with numerous pharmaceutical companies and the National Institutes of Health (NIH) in bringing new drugs for Parkinson disease to the market including pramipexole, entacapone, rotigotine and rasagiline.
A collection of grants, awards and other funding available for Parkinson Disease research initiatives
Clinical trials in progress, completed trials, PSG credentialed sites and other related resources
Upcoming Events & Deadlines
- Sep 17, 2016 – Sep 19, 2016 PSG Annual Meeting Sep 17, 2016 – Sep 19, 2016
- Sep 19, 2016 30th Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders Sep 19, 2016